Part 2 of the randomized, open-label, phase III COLUMBUS trial on the benefit of MEK inhibition to BRAF/MEK inhibitor combo therapy of BRAF-mutant melanoma
In this medfyle
Part 2 of the COLUMBUS trial concluded that the addition of binimetinib in advanced BRAFV600-mutant melanoma maintaining the same encorafenib dosage in COMBO300 (i.e., encorafenib 300 mg once daily plus binimetinib 45 mg twice daily) improved PFS, ORR, and tolerability compared with ENCO300 (i.e., encorafenib 300 mg once daily).
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
©2024 Medfyle. All rights reserved.
Original article:
Ascierto PA, Dummer R, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Robert C, Flaherty KT. Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. J Clin Oncol. 2023 Oct 10;41(29):4621-4631. doi: 10.1200/JCO.22.02322. Epub 2023 Jul 28. PMID: 37506329; PMCID: PMC10564308
The summary content was prepared by Marta Castano for Medfyle, and reviewed by Martina Lambertini, MD.
The authors of the original article and the publisher were not involved in the creation of the summary.
